← Back to Search

Other

Citicoline Supplement for Mild Cognitive Impairment

N/A
Recruiting
Led By Victoria Pak, PhD, MS, MTR
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age: 60 years or older
Diagnosis of Mild Cognitive Impairment (MCI)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 3 months
Awards & highlights

Study Summary

This trial will assess if a dietary citicoline supplement impacts sleep and cognition in people with mild cognitive impairment (MCI). It will also evaluate biomarkers that may help predict Alzheimer's.

Who is the study for?
This trial is for people aged 60 or older with Mild Cognitive Impairment (MCI) who have trouble sleeping, as shown by specific sleep quality scores. Participants must speak English and have internet access. It's not for those on certain medications, using choline supplements, with a history of severe head trauma or epilepsy, allergies to Citicoline ingredients, serious health conditions like heart failure or diabetes, psychiatric disorders, sleep apnea, restless legs syndrome or irregular work schedules.Check my eligibility
What is being tested?
The study tests if a dietary supplement called citicoline can improve sleep and cognitive function in individuals with MCI. Researchers will also check if it affects Alzheimer's biomarkers in the body. Participants will either receive the citicoline supplement or a placebo without knowing which one they are taking.See study design
What are the potential side effects?
Citicoline is generally well-tolerated in older adults and has been used safely at similar doses in people with cognitive impairments. However, potential side effects were not explicitly listed; typically such supplements may cause digestive discomfort or allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 60 years old or older.
Select...
I have been diagnosed with Mild Cognitive Impairment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in beta-amyloid 42 levels
Change in percentage of the rapid eye movement (REM) sleep
Change in plasma choline levels
+4 more

Side effects data

From 2016 Phase 4 trial • 62 Patients • NCT02074735
17%
Drowsiness
14%
Dry mouth
14%
Nausea
10%
Diarrhea
7%
Headache
3%
Bruising
3%
Increased energy
3%
Hypertension
3%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Citicoline

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment GroupExperimental Treatment1 Intervention
Participants with MCI will receive dietary citicoline supplements.
Group II: PlaceboPlacebo Group1 Intervention
Participants with MCI will receive a placebo supplement.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Mild Cognitive Impairment (MCI) often focus on enhancing cognitive function, improving sleep, and impacting biomarkers associated with Alzheimer's disease. Citicoline, for example, works by increasing the levels of phosphatidylcholine, a key component of cell membranes, which supports neuronal repair and enhances neurotransmitter function. This is crucial for MCI patients as it can help slow cognitive decline, improve memory, and potentially delay the progression to Alzheimer's disease. Additionally, improving sleep quality can further support cognitive function and overall brain health, making these treatments particularly beneficial for MCI patients.

Find a Location

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,645 Previous Clinical Trials
2,564,450 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,692 Previous Clinical Trials
28,027,114 Total Patients Enrolled
Victoria Pak, PhD, MS, MTRPrincipal InvestigatorEmory University
1 Previous Clinical Trials
20 Total Patients Enrolled
~55 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top